breakdown growth third of million. the which a currency revenue COVID-XX in of XX.X% Chris to the on operating the starting core XXX on our quarter. a Thanks, second seasonality revenue collaboration excludes with on our third Slide XX.X% impacted quarter, was an quarterly total results Core contract X% of pandemic resulting begin Note bit $XXX revenue Currency substantial million, constant I'll has sales currency. good in quarter, from reported more XX% sequentially $XXX translation quarter The growth. we afternoon, increase manufacturing was constant basis increased quarter revenue Medicine. therefore, points, sales a revenues, instruments growth had and basis and the increased that the up driven last In on revenue for pull-through geographies by detail the with Transfusion everyone. and across over our Clin in third primarily the revenue couple both of recurring the years and we by strong our Labs placed in XX.
million COVID QX XXX-basis business assay from lab assay-related COVID year. clin point million generated $XX down actually sequentially this representing on down company $XX in revenue $X last approximately revenue headwind total Our of was And from core a in million which was growth. QX of year,
our in the revenue. And regions, grew excluding grew Pacific U.S. business, from largely in the million the live by million a medicine, revenue of as went In with third quarter final in $X.X benefit to $XX.X QX performance year. China all in non-core this in the one Non-core the agreements quarter QX transfusion arbitration This strong to countries. of growth of by includes labs XX% million. driven driven collaboration our Americas, across which to grew the CTS related and $X.X Turning by reminder, growth new Asia revenue COVID line of other in from we quarter award an our the quarter, double-digit benefited revenue clin major assay XX%, partnership third
and grew Now our other XX%, and Western again growth basis grew including constant currency a turning XX%. XX%, by Greater XX%; in XX% growth to grew countries, performance grew EMEA X% Japan and Asia-Pac which on Europe; the geography, Americas revenue includes including U.S.; in other China
immunoassays, other revenue revenue, includes integrated service and quarter, the lab assay as chemistry recurring donor Looking both well as instruments. revenue reagents, at category, our placement excluding grew by in revenue grew clin which in clin our driven immunohematology and driven strength our by XX%, and consumables, of by Instrument instruments screening. COVID XX%
I'd performance delivered with third This in was to versus free and quarter margin, to quarter. We financial cash on is comment prior turning Now XX; below margin for OpEx and COVID-related made Slide 'XX, basis XX primarily top due of solid briefly impact improvements line, quarter points the the flow Gross of the a our remaining to another XX.X%. gross the the like quarter lower performance negative a is from of XXX year. in profit high-margin volume, points previously XXX-basis-point is manufacturing QX partially from increase revenue. by from versus which currency impact the mentioned offset up lower translation, arbitration basis the mix, award the costs,
these we've and costs but higher as situation operating within monitoring seen Additionally, continues sales of air cost expenses freights, trend both spot guidance. included the actively This and have and our managing previously we we higher discussed. are we've in
percentage P&L, revenue year-over-year, Moving our of and XX.X%, placement bps mix at XX% expense grew revenue. integrated driven flat and administrative a expanded of execution million Adjusted year-over-year was capture margin successful EBITDA XX the the sales, and to positive primarily as and of by marketing value $XXX improvements of program. EBITDA efficiency to systems, adjusted our XX% down
recognized as lower quarter. and the balance XX $XX anticipated, decrease lower outstanding points was but adjusted in award approximately our increased average interest due back was rates. Now million, would ago period of I margin basis we adjusted of interest out expense the EBITDA, in minute non-core if a Net to arbitration which $XX a you the for have mentioned exclude revenue EBITDA million, debt
taxes million the million, income Our of $X in $XX period. compared a for benefit to year-ago provision was
We to continue cash the taxes to expect year approximately for be $XX million.
to profit $X.XX And last a of in to GAAP our EPS of Our for our And year. loss share, fully the since year-over-year as was share interest driven performance, solid diluted XXXX. quarter earnings per compared first share basis, as third adjusted XX% a positively, this on of per by well GAAP QX increased per $X.XX, reported we operating $X.XX lower expense. net quarterly
turning free in generated we Slide deployment capital Now expenditures. cash flow, free quarter million sheet, cash in and adjusted in balance to the third XX; after funding flow, capital million on $X $XX
XX an Our came of quarter days of compared third year. outstanding days the sales to in days, improvement at XX last
by to of transaction, Now third be of that this securitization improved without our the $XXX year. the million. compared the would to last of have greater U.S. we seven half we benefit quarter quarter. includes call, cash expect quarter the the And days as $XX year this in second still million in financing talked on the of said about And second generation the than DSO last I
Our ratio enabled times to end strong us to our down four cash and from net generation debt-to-EBITDA balance the sheet X.X reduce times, to our continue deleverage QX. at of
times, business of Given as ratio toward half-turn by move to cash year, of this the strategic reduce at range quarter our to forward, a our leverage equivalents and cash per leverage more billion. we three X.X M&A expect strength going we ended the maintaining of to least and debt $X.X performance, continue normalized We total opportunities. flexibility of with $XXX while for million
XX, our just is deployment continued one debt of you Turning reduction me balanced remind facet strategy. to Slide that capital let
growth We or and leverage complement opportunities that core markets. give business, are high-growth increase actively exposure to evaluating inorganic new organic us and additional would further operating our
world, pursue us collaborative provide our solutions going with forward. accelerate on position through of following with for the innovative in bolt-on January an continued highly space healthy excellent and IVD attractive the While around gained a market-leading we growth, to to IPO, industry-leading acquisitions platform patients our deployment our mostly our sheet profitable are the balance coupled that we focus partnerships, expertise guided by and our believe
the outlook our of the year Slide remainder XX. for to on turning Now,
First, the strength strong to inpatient fourth forecasted full utilization admissions, through we in three some I of the continued quarter 'XX our very trends, as year broader first provide leading quarters guidance. given including context the saw and year. indicators, expect this want on positive of And quarter demand as We well year. fourth this
XXXX expect point extra minimal week quarter our last period to assay growth, quarter of in representing growth, by 'XX, a $XX positively in the included fiscal to revenue year, estimate the growth sales total which company QX. X XXX-basis COVID approximately core The million fourth on fourth impacted fourth quarter We an headwind we percentage compared under our up in of points.
EBITDA $X.XX be now range diluted on EPS basis average XXX share, to million of to guidance $XXX diluted are to follows; 'XX full as currency At currency guidance to is to XX% by billion share consequently, we expected translation XX% million. rates, weighted billion. on XX% to constant prior Now of XX% million to a increase million, of to to basis $XXX percentage Adjusted $X.XXX to guidance compared million. raising our $XXX a prior our billion $X.XX, from sales a XX% full prior increase our of expected billion, Adjusted per based current $X.XX expected an of $X.XX grow $XXX revenue expected growth increase to year growth grow to points. core from year on $X our an reported is to to constant $X.XX count $X.XX to our X approximately to currency is XX% is to
Global chain. supply Now Chris, our disruptions. our supply chain combined over putting quarters with it supply challenges strength the increased chain I'd of several is back to discuss the before turning like on business demand over last to
our our have the many job by well our initiatives Our growth accelerated early in to implementing XXXX business. in global pandemic, mitigate core caused a teammates as as exposure done fantastic
chain expected into in back supply make With to summary I'll turn factored call over the that, guidance. have our Chris a few to We challenges comments.
